Triple Play: Lilly Acquires Three Developers of Infectious Disease Vaccines for Up-to-$3.8B
RFK Jr. adviser Calley Means and Kennedy’s son Finn attended the Enhanced Games, the pro-doping athletic competition and biohacking extravaganza that took place over the weekend...
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
Worth close to $4 billion combined, the acquisitions of Curevo, Limmatech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio. Read More
Olympus is pushing deeper into prostate cancer care with the acquisition of BioProtect, an Israeli company whose biodegradable balloon spacer has been used in more than...
SLAS has revealed the winners of its New Product Awards, drawing the Vienna conference to a close. Among the winners are Bionomous for its Sortivo technology, a next-generation large-particle sorter,...
MOSAIC: Multimodal In Vivo Imaging Data Powers AI Models for Living Systems
WASHINGTON — President Donald Trump is getting a medical exam on Tuesday, putting his health under renewed public scrutiny after he has worked to dismiss concerns over his age and stamina. The...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi! Hope you had a...
Eli Lilly, with a busier-than-ever business development team, has made a major vaccine play‚ months after hiring veteran vaccine regulator Peter Marks following his FDA departure.